TWS-119 is a potent and selective inhibitor of glycogen synthase kinase-3β (IC50 = 30 nM). TWS119 could activate Wnt/β-catenin pathway and up-regulate the expression of CD62L in a dose-dependent manner, but it decreased the expression of CD107a. Glycogen synthase kinase (GSK)-3, a constitutively active serine-threonine kinase, acts as a key regulator of major signaling pathways, including the Wnt, Hedgehog, and Notch pathways.
GSK-3 Inhibitors Related Prodcuts:
CHIR-99021; AR-A014418; TDZD-8; 2-D08; BIO-Acetoxime; 5-Bromoindole; CP21R7 (CP21); SB-216763